Literature DB >> 16302334

Spurious absence of signal on 3D time-of-flight MR angiograms on 1 and 3 tesla magnets in cerebral arteries associated with a giant ophthalmic segment aneurysm: the need for alternative techniques.

B Thomas1, S Sunaert, K Thamburaj, G Wilms.   

Abstract

There are many high-resolution MR angiographic techniques available today for the evaluation of circle of Willis. We report a case of bilateral aneurysms of the carotico-ophthalmic segment, the left one being a giant aneurysm, in a 41-year-old woman. She underwent different MRA sequences on both 1 and 3Tesla magnets and a digital subtraction angiography. 3D time-of-flight angiograms can give spurious information on giant aneurysms and other techniques like phase contrast and dynamic contrast enhanced angiographies can supplement if not replace it. High field strength improves the objective quality of MR angiograms, but in the case of large aneurysms, intra aneurysmal and distal vessel signal loss can be a significant problem.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16302334

Source DB:  PubMed          Journal:  JBR-BTR        ISSN: 0302-7430


  3 in total

1.  Surveillance of Unruptured Intracranial Saccular Aneurysms Using Noncontrast 3D-Black-Blood MRI: Comparison of 3D-TOF and Contrast-Enhanced MRA with 3D-DSA.

Authors:  C Zhu; X Wang; L Eisenmenger; B Tian; Q Liu; A J Degnan; C Hess; D Saloner; J Lu
Journal:  AJNR Am J Neuroradiol       Date:  2019-05-23       Impact factor: 3.825

2.  Does black blood MRA have a role in the assessment of intracerebral aneurysms?

Authors:  Stavros M Stivaros; Jonathan N Harris; William Adams; Alan Jackson
Journal:  Eur Radiol       Date:  2008-08-09       Impact factor: 5.315

3.  Follow-up of coiled cerebral aneurysms at 3T: comparison of 3D time-of-flight MR angiography and contrast-enhanced MR angiography.

Authors:  N Anzalone; F Scomazzoni; M Cirillo; C Righi; F Simionato; M Cadioli; A Iadanza; M A Kirchin; G Scotti
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-12       Impact factor: 3.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.